Sonnet BioTherapeutics stock soars after $888 million crypto deal

Sonnet BioTherapeutics (NASDAQ:SONN) stock surged 290% following an $888 million business combination that will transform the biopharmaceutical company into Hyperliquid Strategies Inc., a cryptocurrency treasury focused on HYPE tokens. The new Nasdaq-listed entity, formed with Rorschach I LLC and backed by Atlas Merchant Capital and Paradigm Operations LP, will hold approximately $583 million in HYPE tokens and over $305 million in cash, attracting significant investment from prominent crypto funds including Galaxy Digital and Pantera Capital. Bob Diamond of Atlas Merchant Capital will chair the new entity, marking a notable strategic pivot for a publicly traded company into the digital asset space, while Sonnet's biotech assets will continue development as a wholly-owned subsidiary.

Analysis

Sonnet BioTherapeutics (SONN) is undergoing a fundamental transformation from a biopharmaceutical firm into a cryptocurrency treasury, a strategic pivot that triggered a 290% surge in its stock price. The $888 million business combination will create Hyperliquid Strategies Inc., a publicly-listed entity on Nasdaq capitalized with approximately $583 million in HYPE tokens and over $305 million in cash. The deal's structure is notable, effectively using a public company shell to bring a crypto-focused strategy to market, backed by significant institutional capital from Atlas Merchant Capital, Paradigm, Galaxy Digital, and Pantera Capital. The appointment of established finance executives, including Bob Diamond as Chairman and former Boston Fed President Eric Rosengren to the board, is a clear attempt to lend institutional credibility to the venture. Sonnet's legacy biotech assets are not being discarded but rather segregated into a wholly-owned subsidiary, with existing shareholders receiving a Contingent Value Right (CVR) that provides continued, albeit separate, exposure to their potential success. This transaction completely redefines the company's investment thesis, shifting its primary risk exposure from clinical trial outcomes to the volatility of digital assets and the execution of a novel treasury management strategy.

Key Decisions for Investors

• Investors should recognize that the company's risk profile has fundamentally shifted from biotechnology development to the high volatility of the digital asset market, requiring a complete re-evaluation of its place within a portfolio.
• Given the 290% stock surge, existing shareholders should consider trimming positions to realize gains, as the current valuation has priced in significant optimism for a novel and unproven crypto treasury strategy.
• Key future catalysts to monitor are the successful closing of the transaction, the price stability of the HYPE token which will form the majority of the new entity's assets, and the strategic execution of the new, high-profile management team.